I think the one thing that may limit MSB with respect to this trial is that they had an N of 566, whereas Novartis had an N of 4822.
A sample size that large makes it easier to find significance when breaking down outcomes for specific subgroups.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.36 |
Change
-0.070(2.88%) |
Mkt cap ! $3.020B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.42 | $2.34 | $8.337M | 3.518M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6198 | $2.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.37 | 5376 | 2 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| MSB (ASX) Chart |